AFP and metabolic dysfunction-associated steatotic liver disease: On multivariable analysis including NAFLD HCC, race/ethnicity, tumor burden, MELD-Na, and AFP at listing, and number of LRT, there was no statistically significant difference between NAFLD-HCC and other-HCC patients (HR, 0.65; 95% CI, 0.30-1.41; P = 0.28), while factors that were associated with waitlist dropout included tumor burden (1 lesion 3–5 cm: HR, 2.25; 95% CI, 1.51-3.23; P < 0.001 or 3 lesions: HR, 3.00; 95% CI, 1.70-5.30; P < 0.001), MELD-Na at listing ≥15 (HR, 1.55; 95% CI, 1.05-2.28; P = 0.03), and AFP at listing ≥20 ng/mL (HR, 1.88; 95% CI, 1.36-2.60; P < 0.001).